ReviewClinical pharmacokinetics2007
Strategies to improve drug delivery across the blood-brain barrier.
Review in Clinical pharmacokinetics, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 102 citations in OpenAlex.
- Novel untethered micro-robotic platform developed for minimally invasive ultra-selective microsurgical procedures and targeted drug delivery: Preliminary characterization of tissue response to intraparenchymal navigation in ovine brain.Surgical neurology international · 2025Article
- Towards Symmetric Thioamides: Microwave-Aided Synthesis of Terephthalic Acid Derivatives.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Molecular Imaging of Ultrasound-Mediated Blood-Brain Barrier Disruption in a Mouse Orthotopic Glioblastoma Model.Pharmaceutics · 2022Article
- Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems.Current neuropharmacology · 2021Article
- Heparin-binding Peptides as Novel Therapies to Stop SARS-CoV-2 Cellular Entry and Infection.Molecular pharmacology · 2020Review
- Review
- Abrogated Caveolin-1 expression via histone modification enzyme Setdb2 regulates brain edema in a mouse model of influenza-associated encephalopathy.Scientific reports · 2019Article
- Peptide Mediated Brain Delivery of Nano- and Submicroparticles: A Synergistic Approach.Current pharmaceutical design · 2018Article
- Niosome: A Promising Nanocarrier for Natural Drug Delivery through Blood-Brain Barrier.Advances in pharmacological sciences · 2018Review
- Mapping Extracellular pH of Gliomas in Presence of Superparamagnetic Nanoparticles: Towards Imaging the Distribution of Drug-Containing Nanoparticles and Their Curative Effect on the Tumor Microenvironment.Contrast media & molecular imaging · 2017Article
- Anti-cancer Antibody Trastuzumab-Melanotransferrin Conjugate (BT2111) for the Treatment of Metastatic HER2+ Breast Cancer Tumors in the Brain: an In-Vivo Study.Pharmaceutical research · 2016Article
- Localized Down-regulation of P-glycoprotein by Focused Ultrasound and Microbubbles induced Blood-Brain Barrier Disruption in Rat Brain.Scientific reports · 2016Article
- In vivo Functional Evaluation of Increased Brain Delivery of the Opioid Peptide DAMGO by Glutathione-PEGylated Liposomes.Pharmaceutical research · 2016Article
- Exosomes: a new weapon to treat the central nervous system.Molecular neurobiology · 2014Review
- Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer.Case reports in oncology · 2014Article
- Clinical pharmacokinetics of antibacterials in cerebrospinal fluid.Clinical pharmacokinetics · 2013Review
- Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier.Proceedings of the National Academy of Sciences of the United States of America · 2013Article
- Design and exploratory neuropharmacological evaluation of novel thyrotropin-releasing hormone analogs and their brain-targeting bioprecursor prodrugs.Pharmaceutics · 2013Article
- Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial.OncoTargets and therapy · 2012Article
- Controlled ultrasound-induced blood-brain barrier disruption using passive acoustic emissions monitoring.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The blood-brain barrier (BBB), together with the blood-cerebrospinal-fluid barrier, protects and regulates the homeostasis of the brain. However, these barriers also limit the transport of small-molecule and, particularly, biopharmaceutical drugs such as proteins, genes and interference RNA to the brain, thereby limiting the treatment of many brain diseases. As a result, various drug delivery and targeting strategies are currently being developed to enhance the transport and distribution of drugs into the brain. In this review, we discuss briefly the biology and physiology of the BBB as the most important barrier for drug transport to the brain and, in more detail, the possibilities for delivering large-molecule drugs, particularly genes, by receptor-mediated nonviral drug delivery to the (human) brain. In addition, the systemic and intracellular pharmacokinetics of nonviral gene delivery, together with targeted brain imaging, are reviewed briefly.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.